Calcium Carbonate

Calcium carbonate, a common dietary supplement and medication, has been the subject of several clinical trials investigating its efficacy in treating various medical conditions. These studies aim to evaluate its effects on bone health, kidney function, and other aspects of human physiology. This article summarizes the findings from recent clinical trials using calcium carbonate, providing insights into its potential benefits and applications in healthcare.

Table of Contents

What is Calcium Carbonate?

Calcium carbonate is a common medication used to supplement calcium in the body. It’s often known by brand names such as Tums[1]. This compound contains a high concentration of elemental calcium, specifically 42% per gram, making it an efficient source of calcium supplementation[2].

Medical Uses of Calcium Carbonate

Calcium carbonate is used to treat or prevent various medical conditions:

  • Chronic Kidney Disease (CKD): It’s used to manage high phosphate levels (hyperphosphatemia) in patients with CKD, especially those on dialysis[3].
  • Hypoparathyroidism: This condition occurs when the body doesn’t produce enough parathyroid hormone, leading to low calcium levels. Calcium carbonate is used to manage this condition[2].
  • Osteoporosis Prevention: It’s used to prevent bone loss in conditions like osteoporosis[4].
  • Vitamin D Deficiency: Often combined with vitamin D supplements to improve calcium absorption[5].
  • Postpartum Hemorrhage Prevention: Research is being conducted to investigate if calcium carbonate can help reduce bleeding after childbirth[1].

Dosage and Administration

The dosage of calcium carbonate can vary depending on the condition being treated and the patient’s specific needs. Here are some examples from clinical trials:

  • For hyperphosphatemia in CKD: Doses ranged from 3000 mg to 6500 mg per day, divided into three doses taken with meals[3].
  • For hypoparathyroidism: Doses of 1500 mg to 3000 mg per day, divided into two doses[2].
  • For vitamin D supplementation after parathyroid surgery: 1000 mg per day, divided into two 500 mg doses[5].

It’s important to note that calcium carbonate is typically taken with food to improve absorption. Always follow your doctor’s instructions regarding dosage and timing of medication[2].

Comparison with Other Medications

Calcium carbonate is often compared to other medications used for similar purposes:

  • Lanthanum Carbonate: This is another phosphate binder used in CKD. Some studies suggest it may have benefits over calcium carbonate in terms of cardiovascular outcomes and bone health[6].
  • Sevelamer Carbonate: This non-calcium-based phosphate binder may have advantages in terms of reducing inflammation and oxidative stress in diabetic patients with kidney disease[7].
  • Calcium Citrate: This form of calcium may be better absorbed in certain conditions, such as achlorhydria (lack of stomach acid) or in patients taking proton pump inhibitors[2].

Side Effects and Precautions

While calcium carbonate is generally well-tolerated, it can cause some side effects:

  • Gastrointestinal Issues: It may cause flatulence, constipation, and general gastrointestinal discomfort[2].
  • Kidney Stones: Long-term use of high doses may increase the risk of kidney stones in some patients[2].
  • Hypercalcemia: Excessive intake can lead to high blood calcium levels, which can be harmful[4].

Patients with certain conditions, such as kidney problems or a history of kidney stones, should use calcium carbonate under close medical supervision[2].

Ongoing Research

Several clinical trials are currently investigating the use of calcium carbonate in various conditions:

  • Its potential role in reducing postpartum hemorrhage[1].
  • Comparison with other phosphate binders in terms of long-term cardiovascular outcomes in dialysis patients[6].
  • Its effectiveness when combined with vitamin D supplementation after parathyroid surgery[5].

These ongoing studies aim to further our understanding of calcium carbonate’s benefits and potential risks in different patient populations.

Aspect Details
Main Uses Treatment of calcium/vitamin D deficiencies, management of hyperphosphatemia in CKD, comparator in phosphate binder trials
Administration Oral tablets or chewable forms, typically taken multiple times daily with meals
Dosage Range Varies by study, from 500mg to 3000mg daily
Compared Medications Lanthanum carbonate, sevelamer carbonate, calcium citrate
Studied Conditions Chronic kidney disease, hyperphosphatemia, vitamin D deficiency, hypoparathyroidism, potential prevention of postpartum hemorrhage
Outcome Measures Serum calcium levels, phosphate levels, PTH levels, bone density, cardiovascular calcification
Potential Side Effects Gastrointestinal disorders (flatulence, constipation)
Special Considerations Often combined with vitamin D supplementation, dosage adjustments may be needed based on individual patient factors

Ongoing Clinical Trials on Calcium Carbonate

  • Comparing 7-Day and 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Iceland
  • Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Bulgaria Estonia Hungary Latvia Poland Slovakia
  • Study on the Effectiveness and Safety of Eneboparatide in Patients with Chronic Hypoparathyroidism

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Spain
  • Study on the Effectiveness and Safety of Eneboparatide, Calcitriol, and Calcium Carbonate for Patients with Chronic Hypoparathyroidism

    Not recruiting

    1 1 1
    Investigated diseases:
    Belgium Denmark France Germany Hungary Italy +4
  • Study of encaleret compared to standard care in patients with autosomal dominant hypocalcemia type 1

    Not recruiting

    1 1 1 1
    Belgium Czechia Denmark France Italy The Netherlands
  • Study on Treating Osteogenesis Imperfecta in Patients Using Teriparatide and Zoledronic Acid

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Denmark France Ireland The Netherlands
  • Study of AZD9550 and AZD6234 combination for weight loss in people with obesity or overweight with health complications

    Not recruiting

    1 1
    Investigated diseases:
    Germany
  • Study of SKB264 and Pembrolizumab for Treating Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Romania Spain
  • Study of SKB264 for Patients with Advanced Solid Tumors Not Responding to Standard Treatments

    Not recruiting

    1 1 1
    Investigated diseases:
    Italy Spain
  • Study on the Safety and Effects of AZD9550 for Overweight and Obese Patients with Non-Alcoholic Steatohepatitis (NASH) with or without Type 2 Diabetes

    Not recruiting

    1 1
    Investigated diseases:
    Austria Germany Sweden

Glossary

  • Hyperphosphatemia: A condition characterized by abnormally high levels of phosphate in the blood, often seen in patients with chronic kidney disease.
  • Chronic Kidney Disease (CKD): A long-term condition where the kidneys do not work as well as they should, potentially leading to complications like hyperphosphatemia.
  • Hypoparathyroidism: A condition where the parathyroid glands produce too little parathyroid hormone, leading to low calcium levels in the blood.
  • Parathyroid Hormone (PTH): A hormone produced by the parathyroid glands that regulates calcium levels in the body.
  • Vitamin D: A fat-soluble vitamin that helps the body absorb calcium and is often supplemented along with calcium carbonate.
  • Serum Calcium: The amount of calcium present in the blood, which is an important measure in many of these clinical trials.
  • Phosphate Binder: A medication used to lower phosphate levels in the blood, often used in patients with kidney disease.
  • Lanthanum Carbonate: A non-calcium, non-aluminum phosphate binder used to treat hyperphosphatemia in patients with end-stage renal disease.
  • Sevelamer Carbonate: Another type of phosphate binder used to control serum phosphorus in patients with chronic kidney disease.
  • Postpartum Hemorrhage: Excessive bleeding after childbirth, which some studies are investigating whether calcium carbonate supplementation can help prevent.

References

  1. https://clinicaltrials.gov/study/NCT06650930
  2. https://clinicaltrials.gov/study/NCT03425747
  3. https://clinicaltrials.gov/study/NCT01696279
  4. https://clinicaltrials.gov/study/NCT02237534
  5. https://clinicaltrials.gov/study/NCT00982722
  6. https://clinicaltrials.gov/study/NCT01578200
  7. https://clinicaltrials.gov/study/NCT01493050